Subcutaneous amivantamab every 4 weeks plus lazertinib shows high response rate in EGFR-mutated NSCLC

Published Date: 10 Sep 2025

A new analysis from the PALOMA-2 study shows that subcutaneous administration of amivantamab every four weeks (Q4W), in combination with daily oral lazertinib, yields a high objective response rate in patients with previously ...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Short Shrift in Cancer Funding; Bypassing Familiar for Distant; Testing for BRCA.

2.

Pre-operative evaluation of ovarian cancer patients using DWI-MRI is helpful.

3.

Rural colon cancer patients face higher risks, but minimally invasive surgery could narrow gap

4.

Novel topical fluorescent imaging technique rapidly and safely detects basal cell carcinoma

5.

Potential new therapy for childhood brain cancer could heal treatment-resistant tumors


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot